Baird Capital’s global private equity team has invested in Blue Matter Consulting (Blue Matter), a strategic consulting firm serving the life sciences industry. Financial details of the deal have not been disclosed.Founded in 2012, Blue Matter provides consultancy services to the global pharmaceutical sector, principally in the areas of product and portfolio strategy, organisational design, and product launch planning and readiness. Blue Matter is a global business with offices in San Francisco, New York, London, Zurich, and Berlin. The company has a wide range of therapeutic expertise, with a deep focus on oncology and rare diseases.
“We are so pleased to bring Blue Matter into the Baird Capital portfolio,” says Gordon Pan, President of Baird Capital. “Ashwin and Emily are brilliant partners, and their professional and personal missions are a natural fit with our diverse and tenured group.”
Blue Matter’s international client base includes many of the world’s largest pharmaceutical companies that value their ability to bring real insight to their most critical decisions. Co-Founders and Managing Partners Ashwin Dandekar and Emily Hua have decades of experience in the life sciences and pharmaceutical consulting, with proven track records advising many of the biopharmaceutical industry’s most innovative companies and product teams.
“It was a natural connection when we met Baird Capital and its leadership team,” says Dandekar. “We believe this partnership will accelerate our growth strategy on multiple fronts, helping to drive faster organic growth and expanding our ability to consider strategic acquisitions. We look forward to growing Blue Matter together.”
“We’re very excited about this relationship,” adds Hua. “Baird Capital’s investment will greatly enhance our ability to invest in our team and do more of what we do best: helping push the boundaries of science and technology to improve people’s lives.”
